Author: Metzger, Vincent T.; Lloyd-Smith, James O.; Weinberger, Leor S.
Title: Autonomous Targeting of Infectious Superspreaders Using Engineered Transmissible Therapies Document date: 2011_3_17
ID: 0gt21051_27
Snippet: Detailed experimental and theoretical study is required to predict the ultimate direction of TIP evolution, but the competing selection pressures may effectively constrain TIP phenotypes to a range that assures low HIV viral load and low HIV disease prevalence. TIP evolution is likely to be dominated by mutational processes, since recombination between TIPs and wild-type HIV appears to be severely limited by fundamental sequence-homology constrai.....
Document: Detailed experimental and theoretical study is required to predict the ultimate direction of TIP evolution, but the competing selection pressures may effectively constrain TIP phenotypes to a range that assures low HIV viral load and low HIV disease prevalence. TIP evolution is likely to be dominated by mutational processes, since recombination between TIPs and wild-type HIV appears to be severely limited by fundamental sequence-homology constraints on retroviral recombination [44] that render recombination between full-length 9.7 kb HIV genomes and shorter lentiviral genomes (e.g. TIP) non-competent for integration [18] . This molecular argument against recombination between HIV and TIP is also supported by data from murine models [45, 46] and the recent human clinical trial data [17] , neither of which detected recombination between wild-type HIV-1 and shorter lentiviral therapy vectors.
Search related documents:
Co phrase search for related documents- clinical trial and HIV genome: 1
- clinical trial and HIV viral load: 1, 2, 3, 4
- clinical trial and lentiviral therapy vector: 1
- clinical trial and murine model: 1, 2, 3, 4, 5
- clinical trial and selection pressure: 1, 2, 3
- clinical trial and therapy vector: 1, 2
- clinical trial and viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and wild type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- disease prevalence and HIV disease prevalence: 1, 2, 3, 4, 5, 6
- disease prevalence and HIV viral load: 1
- disease prevalence and murine model: 1
- disease prevalence and selection pressure: 1, 2
- disease prevalence and sequence homology: 1
- disease prevalence and therapy vector: 1
- disease prevalence and viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
Co phrase search for related documents, hyperlinks ordered by date